Tango Therapeutics, Inc. TNGX
- Market cap
- $4.2B
- P/E
- 0.0×
Follow TNGX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.83 | 8.90 | 3.18 | 2.47 | 2.70 | 1.03 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 11.83 | 18.84 | 11.00 | 13.03 | 13.01 | 11.20 |
High Price
|
|||
| — | — | — | — | 4 | 91 | 110 | 140 | 155 | 137 |
Employees
|
|||
| — | — | — | — | 2 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 8 | 37 | 25 | 37 | 42 | 62 |
Revenue
|
|||
| — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | (52) | (58) | (108) | (102) | (130) | (102) |
EBT
|
|||
| — | — | — | — | (678.84%) | (156.43%) | (434.92%) | (278.18%) | (309.24%) | (162.85%) |
EBT Margin
|
|||
| — | 0 | — | 0 | (52) | (58) | (108) | (102) | (130) | (102) |
Net Income
|
|||
| — | — | — | — | 1 | 1 | 2 | (1) | (2) | 0 |
Depreciation
|
|||
| — | — | — | — | 0.24 | 0.60 | 0.28 | 0.39 | 0.39 | 0.54 |
Revenue/Sh
|
|||
| — | — | — | — | (1.63) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
Earnings/Sh
|
|||
| — | — | — | — | 2.19 | (0.96) | (1.24) | (1.25) | (1.20) | (1.20) |
Cash Flow/Sh
|
|||
| — | — | — | — | (0.03) | (0.03) | (0.09) | (0.02) | (0.01) | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | 2.16 | (0.99) | (1.33) | (1.26) | (1.21) | (1.20) |
Free CF/Sh
|
|||
| — | — | — | — | 1.21 | 5.55 | 2.84 | 2.68 | 1.83 | 2.98 |
Book Value/Sh
|
|||
| — | — | — | — | 32 | 62 | 88 | 95 | 109 | 116 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 18.34 | 25.82 | 25.84 | 8.02 | 16.50 |
PS Ratio
|
|||
| — | — | — | — | 1.51 | 1.97 | 2.57 | 3.73 | 1.69 | 2.97 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | 5.23 | 11.07 | 16.59 | 1.89 | 10.99 |
EV/Sales
|
|||
| — | — | — | — | 0.00 | (3.16) | (2.36) | (5.07) | (0.60) | (4.90) |
EV/FCF
|
|||
| — | — | — | — | 70 | (60) | (109) | (118) | (132) | (139) |
Op' Cash Flow
|
|||
| — | — | — | — | (1) | (2) | (8) | (2) | (1) | (1) |
Capex
|
|||
| — | — | — | — | 69 | (61) | (117) | (120) | (132) | (140) |
FCF
|
|||
| — | — | — | — | 153 | 452 | 320 | 301 | 228 | 332 |
Working Cap'
|
|||
| — | — | — | — | 8 | 2 | 41 | — | — | — |
Total Debt
|
|||
| — | — | — | — | (190) | (486) | (367) | (338) | (258) | (344) |
Net Debt
|
|||
| — | — | — | — | 39 | 345 | 249 | 253 | 200 | 346 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (50.15%) | (16.46%) | (23.10%) | (24.25%) | (36.24%) | (28.41%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,661.91%) |
ROIC
|
|||
| — | — | — | — | (20.50%) | (30.38%) | (36.41%) | (40.49%) | (57.58%) | (37.23%) |
ROE
|
|||
Tango Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ABCL AbCellera Biologics Inc. | $4.2B | 0.0× | Compare |
| VKTX Viking Therapeutics, Inc. | $4.3B | 0.0× | Compare |
| RLAY Relay Therapeutics, Inc. | $3.9B | 0.0× | Compare |
| EWTX Edgewise Therapeutics, Inc. | $4.4B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CELC Celcuity, Inc. | $3.9B | 0.0× | Compare |
| TLX Telix Pharmaceuticals Limited | $3.9B | — | Compare |
| ACAD ACADIA Pharmaceuticals Inc. | $3.8B | 9.2× | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | 0.0× | Compare |
Tango Therapeutics, Inc. (TNGX) key facts
- Tango Therapeutics, Inc. (TNGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Tango Therapeutics, Inc. reported a net loss of $101.6 million, or a loss of $0.87 per share, for fiscal 2025.
- As of September 25, 2026, TNGX traded at $24.92, a market capitalization of $4.2 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 59.9× sales.
- Return on equity was −37.2% and debt-to-equity 0.00.
Tango Therapeutics, Inc. (TNGX) Latest News
11 Aug
Tango Therapeutics reported second quarter 2026 financial results and business highlights. Quarterly results and updates supply performance data that can shift near-term valuation.
23 Jul
FDA accepts RVMD's filing for Daraxonrasib in pancreatic cancer. RVMD Daraxonrasib filing acceptance creates competitive pressure for TNGX in pancreatic cancer oncology space.
15 Jul
Tango Therapeutics (TNGX) stands to gain revenues from Vopimetostat combined with KRAS inhibitors. Revenue potential from Vopimetostat plus KRAS inhibitor combination is likely to materially lift TNGX financial results and investor outlook.
2 Jul
Tango Therapeutics aligns operations with emerging precision oncology trend projected for 2026. Adoption of new precision oncology trend signals major strategic positioning that can alter company trajectory and investor sentiment.
TNGX stock outlook depends on Vopimetostat success and 2026 catalysts. Vopimetostat and 2026 catalysts represent major milestones that could reshape TNGX trajectory.
11 Jun
Daraxonrasib Phase 3 pancreatic cancer survival data may alter the investment case for RVMD. Phase 3 data on competing RAS inhibitor in pancreatic cancer may shift TNGX competitive positioning.
9 Jun
Tango Therapeutics priced a $600 million upsized public offering. $600 million capital raise funds pipeline development while diluting existing shareholders.
Tango Therapeutics stock surged 53% after early pancreatic cancer study results showed promising data. Positive early pancreatic cancer study data triggered 53% stock jump with major implications for company prospects.
Tango Therapeutics stock surges on positive pancreatic cancer trial data. Positive pancreatic cancer trial data signals major pipeline progress capable of shifting company trajectory and investor sentiment.
Tango Therapeutics (TNGX) shares surge after positive pancreatic cancer trial results. Positive pancreatic cancer trial results drive major stock gains and reposition company trajectory.
8 Jun
Tango Therapeutics reports standout pancreatic cancer trial results that trigger a sharp stock price surge. Breakthrough pancreatic cancer data can fundamentally redefine Tango Therapeutics' competitive position and long-term prospects.
Tango Therapeutics stock surges 42% on unprecedented clinical data for pancreatic cancer treatment. Unprecedented pancreatic cancer data triggers 42% stock surge and redefines long-term company trajectory.
Tango Therapeutics (TNGX) shares surged 47% after reporting strong pancreatic cancer trial results. Positive pancreatic cancer trial results can fundamentally boost company valuation and future prospects.
Tango Therapeutics, Inc. (TNGX) proposes a $500 million public offering. $500 million public offering secures major capital for operations but dilutes shares and pressures stock price.
Tango Therapeutics pancreatic cancer trial data labeled groundbreaking by Wolfe Research, sending TNGX stock to an all-time high. Groundbreaking trial data in core oncology program drives all-time high share price and materially improves long-term commercial prospects.
Tango Therapeutics reported initial Phase 1/2 trial results for its pancreatic cancer drug candidate showing improved survival rates. Shares rose in pre-bell trading. Positive early clinical data on lead pipeline asset drives share gains and signals material progress toward future milestones for Tango Therapeutics.
Tango Therapeutics announced that Vopimetostat combined with Daraxonrasib achieved a 92% objective response rate in pancreatic cancer. Strong clinical results on a novel oncology combination can materially lift valuation, pipeline value and investor sentiment.
5 Jun
Tango Therapeutics (TNGX) stands to gain from upcoming Pancreatic Ductal Adenocarcinoma data announcement. Data readout on pancreatic cancer program can materially shift company trajectory and investor sentiment.
29 May
Tango Therapeutics stock surged 840%. An investment fund disclosed buying an additional $164 million in shares. Large fund purchase signals strong institutional support likely to influence investor sentiment and stock trajectory.
21 May
Tango Therapeutics reports wider losses and boardroom changes, prompting reassessment of its valuation. Wider losses and boardroom changes affect financial performance and investor sentiment without fundamentally redefining company trajectory.
16 May
Tango Therapeutics (TNGX) shares fell 10.7% after the company pivoted its pipeline and announced board changes, prompting questions on whether its prior bull case remains intact. Pipeline pivot and board changes represent major strategic and leadership shifts that are likely to significantly alter Tango Therapeutics trajectory and investor sentiment.
13 May
Tango Therapeutics, Inc. (TNGX) reported first quarter 2026 financial results and provided business highlights. Quarterly financial results and business highlights affect key financial performance and investor sentiment.
30 Apr
Tango Therapeutics CEO expresses strong confidence that the company's drug will outperform unprecedented pancreatic cancer treatment results. CEO's bold claim of surpassing unprecedented pancreatic cancer results signals potential major breakthrough, likely driving significant investor enthusiasm and stock gains.
18 Apr
Tango Therapeutics (TNGX) leadership team faces scrutiny over its composition and ability to effectively manage and advance the company's complex oncology drug pipelines in a competitive biotech landscape. Leadership effectiveness critically influences oncology pipeline execution and investor confidence in biotech firms.
15 Apr
Tango Therapeutics appoints new executives, including Chief Development Officer Richard Bryce and Chief Regulatory Officer Lori Kunkel, to accelerate late-stage development of vopimetostat, a PRMT5 inhibitor in Phase 2/3 trials for advanced cancers. Leadership hires directly target acceleration of vopimetostat's late-stage trials, a pivotal pipeline asset poised to drive clinical and market progress.
6 Apr
Stifel and Jefferies raised price targets on Tango Therapeutics (TNGX), signaling increased optimism about the biotech company's future performance. Analyst price target hikes from Stifel and Jefferies boost market sentiment for TNGX but do not fundamentally alter its clinical or operational trajectory.
13 Mar
Analysts show cautious optimism for Tango Therapeutics (TNGX) after earnings, balancing promising pipeline updates against financial challenges and trial timelines. Cautious analyst optimism post-earnings moderately influences investor sentiment and stock trajectory amid pipeline progress and financial hurdles.
9 Mar
Erasca (ERAS) enters dual-target clinical trial collaboration with Tango Therapeutics (TNGX), potentially reshaping Erasca's RAS strategy while advancing Tango's precision oncology pipeline targeting multiple RAS pathways. Dual-target RAS trial partnership with Erasca bolsters Tango's clinical development and competitive positioning in oncology.
7 Mar
Tango Therapeutics (TNGX) stock soared 52% after receiving a buy recommendation. 52% stock surge from buy recommendation drives significant positive investor sentiment and potential trajectory shift.
6 Mar
Tango Therapeutics (TNGX) stock surged to a record high following the announcement of a collaboration deal with ERAS. Inking a collaboration deal with ERAS propelled TNGX stock to record highs, signaling major strategic advancements and boosted investor sentiment.